Fatal asthma

Hypocalcemia (serum level < 2.1 mmol/L) has been reported in healthy subjects following administration of IV (32-agonists that cause an increase in the urinary excretion of calcium. In acute asthma, an increase in urinary excretion of calcium has also been reported in asthmatic patients treated with IV aminophylline. In patients with chronic asthma, the prevalence of hypocalcemia has not been evaluated. In this study, all asthmatic patients had a normal serum calcium level. This finding may not contradict previous studies, as none of our asthmatic patients were receiving IV (32-agonists or IV ami-nophylline during the measurement of their serum electrolytes. Buy best quality medications online at the pharmacy that will make sure your are happy with the prices and the quality of your there whenever you need some treatment and have no idea where to get it.
In this study, the prevalence of an electrolyte abnormality was found to be high, and about 15% of the subjects had two or more abnormal electrolyte levels. Therefore, in patients with chronic asthma and exacerbation, care should be taken during acute management to avoid the adverse effects of broncho-dilator therapy. Nebulized (32-agonists and IV ami-nophylline are usually the mainstay therapies for asthma exacerbation. So, in the presence of one or more abnormal electrolyte levels (hypomagnesemia, and or hypophosphatemia, and or hypokalemia), the use of such therapies will increase the derangement of the existing abnormal electrolyte levels. Consequently, this may pose potential cardiac and respiratory hazards in the form of myocardial depression, ventricular arrhythmia, and respiratory muscle fatigue, which consequently may increase the incidence of fatal asthma.